



# CLAIMS


1. A compound having high affinity for a dopamine transporter having a formula selected from the group consisting of:




Formula I




Formula II



Formula III



Formula IV



Formula V

wherein:

n is an integer of 1 to 6; X, Y, Z<sub>1</sub> and Z<sub>2</sub> can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, N-alkyl, (C<sub>2</sub>-C<sub>6</sub>) acyloxy, N-alkylene, -SH, -SR, wherein R is from the same group as R<sub>1</sub> and R<sub>2</sub> and can be the same or different than R<sub>1</sub> and R<sub>2</sub>, amino, nitro, cyano, hydroxy, C(=O)OR<sub>6</sub>, -C(=O)NR<sub>5</sub>R<sub>4</sub>, NR<sub>3</sub>R<sub>2</sub>, or S(=O)<sub>k</sub>R<sub>1</sub> wherein k is 1 or 2, and R<sub>1</sub> to R<sub>6</sub> are independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>) alkyl;

R<sub>1</sub>, and R<sub>2</sub> can be the same or different and are hydrogen, (C<sub>1</sub>-C<sub>6</sub>) alkyl, hydroxyalkyl or mercaptoalkyl, -C(=O)OR<sub>1</sub>, cyano, (C<sub>1</sub>-C<sub>6</sub>) alkenyl, (C<sub>2</sub>-C<sub>6</sub>) alkynyl, or 1, 2, 4-oxadiazol-5-yl optionally substituted at the 3-position by Z<sub>4</sub> wherein any (C<sub>1</sub>-C<sub>6</sub>) alkyl, (C<sub>1</sub>-C<sub>6</sub>) alkanoyl, (C<sub>2</sub>-C<sub>6</sub>) alkenyl or (C<sub>2</sub>-C<sub>6</sub>) alkynyl can optionally be substituted by 1, 2 or 3 Z;

Z<sub>4</sub> is (C<sub>1</sub>-C<sub>6</sub>) alkyl or phenyl, optionally substituted by 1, 2 or 3 Z<sub>1</sub>

R<sub>7</sub> can be hydrogen, O or phenyl

R<sub>8</sub> can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl

W is O or S

T is amino or C<sub>1</sub>-C<sub>6</sub> aminoalkyl

A is N or C


T is C<sub>1</sub>-C<sub>6</sub> alkyl or sulfonyl and


V is alkyl (C<sub>0</sub>-C<sub>6</sub>), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R<sub>1</sub> or

R<sub>2</sub> as indicated above and

φ is phenyl, naphthyl, thienyl or pyridinyl.

2. The compound of claim 1 selected from the group consisting of:





3. The compound of any one of claims 1, or 2 which is labeled with a radionuclide.
4. The compound of claim 3 wherein said radionuclide is  $^{99m}\text{Tc}$ .
5. The compound of claim 3 wherein said radionuclide is an iodine isotope.
6. The method for imaging dopamine neurons in a mammal which comprises:  
administering to the mammal an imaging dose of the compound of claim 1 labeled with a radionuclide and detecting binding of the compound in the mammal.
7. The method for imaging dopamine neurons in a mammal which comprises:  
administering to the mammal an imaging dose of the compound of claim 2 labeled with a radionuclide and detecting binding of the compound in the mammal.
8. The method of treating an mammal afflicted with cocaine abuse which comprises:  
administering to the mammal an effective amount of a compound of claim 1.
9. The method of treating an animal afflicted with cocaine abuse which comprises:  
administering to the mammal an effective amount of a compound of claim 2.
10. The method of treating an mammal afflicted with a neurodegenerated disease characterized by a degeneration of dopamine neurons which comprises:  
administering to the mammal an effective amount of the compound of claim 1.

11. The method of treating an mammal afflicted with a neurodegenerated disease characterized by a degeneration of seratonin neurons which comprises:  
administering to the mammal an effective amount of the compound of claim 1.

12. The method of treating a mammal afflicted with a neurodegenerated disease characterized by a degeneration of dopamine neurons which comprises:  
administering to the mammal an effective amount of the compound of claim 2.

13. The method of treating a mammal afflicted with a neurodegenerated disease characterized by a degeneration of seratonin neurons which comprises:  
administering to the mammal an effective amount of the compound of claim 2.